KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
BOSTON, Feb. 11, 2016 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, February 25, 2016 at 8:00 a.m. ET to discuss its fourth quarter and year end 2015 financial results and provide a review of the Auryxia™ (ferric citrate) launch.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 43760032. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
Keryx will announce its financial results for this period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com
Keryx Biopharmaceuticals Contact: Lora Pike Senior Director, Investor Relations T: 617.466.3511 [email protected]
